Literature DB >> 21079193

Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis.

Ruth Dubin1, Michael Shlipak, Yongmei Li, Joachim Ix, Ian H de Boer, Nancy Jenny, Carmen A Peralta.   

Abstract

BACKGROUND: Pentraxin-3 (PTX3), an inflammatory marker thought to be related to vascular inflammation, is elevated in advanced chronic kidney disease (CKD). Whether PTX3 is associated with mild to moderate kidney dysfunction is unknown.
METHODS: We tested associations of proteins in the pentraxin family [PTX3, C-reactive protein (CRP) and serum amyloid protein (SAP)] with estimated glomerular filtration rate by cystatin C (eGFRcys) and microalbuminuria among 2824 participants in the Multi-Ethnic Study of Atherosclerosis. Associations were tested using multivariable linear regression with adjustment for demographics (age, gender, annual income), comorbidities (diabetes, hypertension, smoking, body mass index, low-density lipoprotein, high-density lipoprotein, triglycerides, ACE inhibitor and statin use) and systemic inflammation [interleukin-6 (IL-6)].
RESULTS: Among the 2824 participants, mean age was 62 years and mean eGFRcys was 94 mL/min/1.73 m(2); 25% were white, 25% Chinese, 25% African-American and 25% Hispanic. Among all participants after full adjustment, higher PTX3 was associated with lower eGFRcys independently of IL-6 (β - 3.0 mL/min/1.73 m(2) per unit increase in lnPTX3, P < 0.001). In contrast, CRP and SAP were associated with eGFRcys in demographic adjusted models, but these associations were attenuated after adjustment for comorbidities and IL-6 (lnCRP β - 0.06, P = 0.9; lnSAP β - 0.35, P = 0.7). There was a significant interaction with race/ethnicity (P < 0.001) in the association of PTX3 and eGFRcys. After adjustment for demographics, comorbidities and IL-6, this association was significant in blacks (β - 5.7 mL/min/1.73 m(2) per unit increase in lnPTX3, P = 0.002) but not in Hispanics (β - 2.4, P = 0.1), Chinese (β - 0.91, P = 0.5) or whites (β - 0.26, P = 0.9). PTX3 and CRP, but not SAP, had correlations with microalbuminuria in unadjusted models (Spearman coefficients PTX3 0.05, P = 0.005; CRP 0.07, P < 0.001; SAP 0.013, P = 0.5), but these were attenuated after full adjustment.
CONCLUSIONS: Endovascular inflammation may be an important mechanism associated with early kidney dysfunction, particularly among blacks. This mechanism appears to be independent of IL-6-regulated pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079193      PMCID: PMC3145399          DOI: 10.1093/ndt/gfq648

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  28 in total

1.  Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors.

Authors:  Michelle E Tarver-Carr; Neil R Powe; Mark S Eberhardt; Thomas A LaVeist; Raynard S Kington; Josef Coresh; Frederick L Brancati
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

2.  Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease?

Authors:  J C Whittle; P K Whelton; A J Seidler; M J Klag
Journal:  Arch Intern Med       Date:  1991-07

3.  Distribution and correlates of arterial compliance measures in asymptomatic young adults: the Bogalusa Heart Study.

Authors:  Azad R Bhuiyan; Shengxu Li; Hong Li; Wei Chen; Sathanur R Srinivasan; Gerald S Berenson
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

4.  Cystatin C and the risk of death and cardiovascular events among elderly persons.

Authors:  Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

5.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study.

Authors:  Bruce A Perkins; Robert G Nelson; Betsy E P Ostrander; Kristina L Blouch; Andrzej S Krolewski; Bryan D Myers; James H Warram
Journal:  J Am Soc Nephrol       Date:  2005-03-23       Impact factor: 10.121

6.  Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension.

Authors:  W McClellan; E Tuttle; A Issa
Journal:  Am J Kidney Dis       Date:  1988-10       Impact factor: 8.860

7.  Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.

Authors:  Roberto Latini; Aldo P Maggioni; Giuseppe Peri; Lucio Gonzini; Donata Lucci; Paolo Mocarelli; Luca Vago; Fabio Pasqualini; Stefano Signorini; Dario Soldateschi; Lorenzo Tarli; Carlo Schweiger; Claudio Fresco; Rossana Cecere; Gianni Tognoni; Alberto Mantovani
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

8.  Endothelial dysfunction and oxidative stress in chronic renal failure.

Authors:  Lorenzo Ghiadoni; Adamasco Cupisti; Yale Huang; Paola Mattei; Heloise Cardinal; Stefania Favilla; Paolo Rindi; Giuliano Barsotti; Stefano Taddei; Antonio Salvetti
Journal:  J Nephrol       Date:  2004 Jul-Aug       Impact factor: 3.902

Review 9.  Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity.

Authors:  Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi
Journal:  Vaccine       Date:  2003-06-01       Impact factor: 3.641

10.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

View more
  12 in total

1.  Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Ruth Dubin; Yongmei Li; Joachim H Ix; Michael G Shlipak; Mary Whooley; Carmen A Peralta
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

2.  Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function.

Authors:  Cuma Bulent Gul; Abdulmecit Yildiz; Alparslan Ersoy; Serdar Kahvecioglu; Burak Asiltas; Fatih Yildirim; Selime Ermurat; Saim Sag; Aysegul Oruc; Sumeyye Gullulu; Mustafa Gullulu
Journal:  Int Urol Nephrol       Date:  2015-06-06       Impact factor: 2.370

3.  Kidney function decline in the elderly: impact of lipoprotein-associated phospholipase A(2).

Authors:  Carmen A Peralta; Ronit Katz; Michael Shlipak; Ruth Dubin; Ian DeBoer; Nancy Jenny; Annette Fitzpatrick; Carol Koro; Bryan Kestenbaum; Joachim Ix; Mark Sarnak; Mary Cushman
Journal:  Am J Nephrol       Date:  2011-11-01       Impact factor: 3.754

4.  RNA-seq analysis provide new insights into mapk signaling of apolipoproteinciii-induced inflammation in porcine vascular endothelial cells.

Authors:  Yuan Yue; Hao Jiang; Shouqing Yan; Yao Fu; Chang Liu; Xulei Sun; Menglong Chai; Yan Gao; Bao Yuan; Chengzhen Chen; Lisheng Dai; Jiabao Zhang; Yu Ding
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

Review 5.  Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease.

Authors:  Marijn M Speeckaert; Reinhart Speeckaert; Juan J Carrero; Raymond Vanholder; Joris R Delanghe
Journal:  J Clin Immunol       Date:  2013-02-27       Impact factor: 8.317

6.  Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.

Authors:  Chris T Longenecker; Corrilynn O Hileman; Nicholas T Funderburg; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2014-07-11       Impact factor: 9.079

7.  Pentraxin-3 and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study.

Authors:  Peter J Leary; Nancy S Jenny; R Graham Barr; David A Bluemke; Michael O Harhay; Susan R Heckbert; Richard A Kronmal; João A Lima; Carmen Mikacenic; Russell P Tracy; Steven M Kawut
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

8.  Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population.

Authors:  Norhashimah Abu Seman; Anna Witasp; Wan Nazaimoon Wan Mohamud; Björn Anderstam; Kerstin Brismar; Peter Stenvinkel; Harvest F Gu
Journal:  J Diabetes Res       Date:  2013-11-20       Impact factor: 4.011

9.  Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly.

Authors:  B Sjöberg; A R Qureshi; O Heimbürger; P Stenvinkel; L Lind; A Larsson; P Bárány; J Ärnlöv
Journal:  J Intern Med       Date:  2015-09-09       Impact factor: 8.989

10.  Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima-media thickness.

Authors:  Saim Sag; Abdulmecit Yildiz; Sumeyye Gullulu; Fatih Gungoren; Bulent Ozdemir; Ercan Cegilli; Aysegul Oruc; Alparslan Ersoy; Mustafa Gullulu
Journal:  Springerplus       Date:  2016-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.